Around 6,600 people in England with a serious heart condition will be able to access a new treatment following simultaneous MHRA authorisation and NICE approval. Aficamten, a once-daily pill, has been recommended by NICE and approved by the MHRA for people with obstructive hypertrophic cardiomyopathy (HCM). Clinical trials show aficamten helps people exercise more easily and reduces symptoms of HCM.
6,600 people to benefit from new heart condition treatment
UKPulse Health DeskAficamten, a once-daily pill, has been recommended by NICE and approved by the MHRA for people with obstructive hypertrophic cardiomyopathy (HCM).
- Around 6,600 people in England with HCM will be able to access the new treatment.
- Aficamten is a once-daily pill that helps people exercise more easily and reduces symptoms of HCM.
- The treatment is likely to be as effective as mavacamten, the other NICE-approved treatment for HCM.
Why this matters: This new treatment offers greater choice for patients and the opportunity for more people living with obstructive HCM to benefit from treatment, feel better and live well.
What this means for you: If you have obstructive hypertrophic cardiomyopathy (HCM), you may be eligible for the new treatment aficamten. You should discuss this with your doctor to see if it is suitable for you.